ESMO: Regeneron Mounts Credible Challenge To Keytruda With Libtayo Survival Data In NSCLC
Claims ‘Best-In-Class’ Status
Executive Summary
Libtayo looks to have surpassed all competitors but Merck’s Keytruda in first line NSCLC, but the unique ‘all-comers’ trial design of EMPOWER-Lung-3 complicates the picture.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: an interview with the president of Novartis Pharma; Biogen highlights its pipeline; standout comparative data for Enhertu in breast cancer; Sanofi/Regeneron nip at Keytruda’s heels in first-line lung cancer; and a look at the market prospects for wet AMD.
AstraZeneca’s Imfinzi/Treme Combo Fails To Match Leaders In First-Line Lung Cancer
The immunotherapy drugs fall short of the standard set by Keytruda, but could gain some traction in non-squamous patient group.
4D Pharma Is Latest Biotech Casualty After Creditor Calls Time
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.